Peter M Irving

50PUBLICATIONS
268CO-AUTHORS
Rheumatology and arthritisImmunogenetics (incl. genetic immunology)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Wastewater treatment processesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (50)

|Nov 03, 2026
Longitudinal timepoint assessment of patient-reported clinical disease activity in ulcerative colitis and Crohn's disease: suitability of a rapid Patient-Reported Outcome 2 (PRO-2) assessment.

|Jun 04, 2026
The UK vedolizumab real-life experience study in inflammatory bowel disease (VEST): patient characteristics, drug persistence and patient-centred outcomes.

|Mar 04, 2026
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study.

Bruce E Sands, David B Clemow, Geert D'Haens

|Feb 08, 2026
Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program.

Marla C Dubinsky, María Chaparro, Peter M Irving

|Jan 19, 2026
Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis.

Stefan Schreiber, Silvio Danese, Jean-Frédéric Colombel

|Dec 25, 2025
Effectiveness of etrasimod on disease activity and patient-reported outcomes in ulcerative colitis-EFFECT-UC: a non-interventional, multinational, prospective cohort study protocol.

Gordon W Moran, Shellie J Radford, Alissa Walsh

Pageof 9

Frequent Collaborators

11 joint publications

Nick Kennedy

10 joint publications

Christopher Andrew Lamb

10 joint publications

Mark Samaan

10 joint publications

Timothy Raine